论文部分内容阅读
本研究比较多参数流式细胞术(MPFC)与骨髓细胞形态学分析(BMA)检测B细胞非霍奇金淋巴瘤(B-NHL)骨髓侵犯的临床价值。采用MPFC与BMA对96例B-NHL患者治疗前的骨髓同时进行检测,并进行二者之间的比较。96份骨髓标本中,BMA检测阳性者12例(12.5%),MPFC检测阳性者38例(39.6%),二者比较差异有显著性(p<0.05),12例BMA检测阳性者MPFC检测均为阳性。MPFC检测阴性的患者与MPFC检测阳性的患者的3年预计总生存率无明显差异,但它们的4年预计总生存率分别为(73.18±6.65)%和(44.13±19.55)%,二者差异显著(p<0.05)。结论:MPFC检测B-NHL骨髓侵犯的敏感性高于骨髓细胞形态学检测,MPFC检测阴性患者的4年平均生存率显著高于MPFC检测阳性患者,MPFC检测淋巴瘤骨髓侵犯可能成为淋巴瘤临床分期和预后判断的有效指标之一。
This study compared the clinical value of multiparameter flow cytometry (MPFC) and bone marrow cell morphology analysis (BMA) in detecting B-cell non-Hodgkin’s lymphoma (B-NHL). 96 cases of B-NHL patients were treated with MPFC and BMA simultaneously. Among 96 bone marrow samples, 12 (12.5%) were positive for BMA and 38 (39.6%) were positive for MPFC, the difference was significant (p <0.05) Positive. The 3-year estimated overall survival of MPFC-negative patients and MPFC-positive patients was similar, but their 4-year expected overall survival rates were (73.18 ± 6.65)% and (44.13 ± 19.55)%, respectively Significant (p <0.05). Conclusions: The sensitivity of MPFC in detecting B-NHL bone marrow invasion is higher than that of bone marrow cells. The 4-year mean survival rate of MPFC negative patients is significantly higher than that of MPFC positive patients. MPFC lymphoma bone marrow invasion may become the clinical stage of lymphoma And prognosis of one of the effective indicators.